Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:apitegromabIndication |
spinal muscular atrophy
|
| gptkbp:awarded |
gptkb:Fierce_15_company_(2016)
|
| gptkbp:CEO |
gptkb:Jay_Backstrom
|
| gptkbp:collaboratesWith |
gptkb:Gilead_Sciences
|
| gptkbp:developedBy |
gptkb:apitegromab
|
| gptkbp:focusesOn |
rare diseases
neuromuscular disorders therapeutics targeting the TGF-beta superfamily |
| gptkbp:foundedIn |
2012
|
| gptkbp:founder |
gptkb:Nagesh_Mahanthappa
gptkb:Timothy_Springer |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Scholar Rock
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:numberOfEmployees |
100-200 (approximate, as of 2023)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:SRRK
|
| gptkbp:website |
https://scholarrock.com
|
| gptkbp:bfsParent |
gptkb:Timothy_Springer
|
| gptkbp:bfsLayer |
5
|